2. Паневин Т.С., Елисеев М.С., Шестакова М.В., Насонов Е.Л. Преимущества терапии ингибиторами натрий-глюкозного котранспортера 2 типа у пациентов с сахарным диабетом 2 типа в сочетании с гиперурикемией и подагрой. Терапевтический архив. 2020; 92(5): 110–118.

3. Chung M.C., Hung P.H., Hsiao P.J. et al. Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan. JAMA Netw Open. 2021; 4(11): e2135353. https://dx.doi.org/10.1001/jamanetworkopen.2021.35353.

4. Барскова В.Г., Елисеев М.С., Денисов И.С. с соавт. Частота метаболического синдрома и сопутствующих заболеваний у больных подагрой. Данные многоцентрового исследования. Научно-практическая ревматология. 2012; 50(6): 15–18.

5. Krishnan E., Svendsen K., Neaton J.D. et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008; 168(10): 1104–10. https://dx.doi.org/10.1001/archinte.168.10.1104.

6. Vazquez-Mellado J., Alvarez Hernandez E., Burgos-Vargas R. Primary prevention in rheumatology: the importance of hyperuricemia. Best Pract Res Clin Rheumatol. 2004;18(2): 111–24. https://dx.doi.org/10.1016/j.berh.2004.01.001.

7. Hernandez-Cuevas C.B., Roque L.H., Huerta-Sil G. et al. First acute gout attacks commonly precede features of the metabolic syndrome. J Clin Rheumatol. 2009; 15(2): 65–67. https://dx.doi.org/10.1097/RHU.0b013e31819c0dba.

8. Zuo T., Liu X., Jiang L. et al. Hyperuricemia and coronary heart disease mortality: A meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016; 16(1): 207. https://dx.doi.org/10.1186/s12872-016-0379-z71.

9. Scheen A.J., Van Gaal L.F. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014; 2(11): 911–22. https://dx.doi.org/10.1016/s2213-8587(14)70004-x.

10. Barnett A.H. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med. 2013; 125(5): 92–100. https://dx.doi.org/10.3810/pgm.2013.09.2698.

11. Ferrannini G., Hach T., Crowe S. et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015; 38(9): 1730–35. https://dx.doi.org/10.2337/dc15-0355.

12. Baker W.L., Smyth L.R., Riche D.M. et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. J Am Soc Hypertens. 2014; 8(4): 262–75.e9. https://dx.doi.org/10.1016/j.jash.2014.01.007.

13. Sano M., Chen S., Imazeki H. et al. Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials. J Diabetes Investig. 2018; 9(3): 638–41. https://dx.doi.org/10.1111/jdi.12726.

14. Meier C., Schwartz A.V., Egger A., Lecka-Czernik B. Effects of diabetes drugs on the skeleton. Bone. 2016; 82: 93–100. https://dx.doi.org/10.1016/j.bone.2015.04.026.

15. Lin K.M., Lu C.L., Hung K.C. et al. The paradoxical role of uric acid in osteoporosis. Nutrients. 2019; 11(9): 2111. https://dx.doi.org/10.3390/nu11092111.

16. Ljunggren O., Bolinder J., Johansson L. et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012; 14(11): 990–99. https://dx.doi.org/10.1111/j.1463-1326.2012.01630.x.

17. Bolinder J., Ljunggren O., Johansson L. et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2013; 16(2):159–69. https://dx.doi.org/10.1111/dom.12189.

18. Vasilakou D., Karagiannis T., Athanasiadou E. et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. Ann Intern Med. 2013; 159(4): 262. https://dx.doi.org/10.7326/0003-4819-159-4-201308200-00007.

19. Berhan A., Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord. 2013; 13: 58. https://dx.doi.org/10.1186/1472-6823-13-58.

20. Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. «Алгоритмы специализированной медицинской помощи больным сахарным диабетом» Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова 9-й выпуск. Сахарный диабет. 2019; 22(S1–1): 1–144. Dedov I.I., Shestakova M.V., Mayorov A.Yu. et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Sakharnyy diabet = Diabetes Mellitus. 2019; 22(S1–1): 1–144 (In Russ.)]. https://dx.doi.org/10.14341/DM221S1. EDN: LDOTJF.

21. Терещенко С.Н., Шестакова М.В., Агеев Ф.Т. с соавт. Целесообразность назначения дапаглифлозина для профилактики неблагоприятных исходов хронической сердечной недостаточности у пациентов со сниженной фракцией выброса. Резолюция совета экспертов. Российский кардиологический журнал. 2020; 25(5): 114–120.

22. Orso F., Fabbri G., Maggioni A.P. Epidemiology of heart failure. Handb Exp Pharmacol. 2017; 243: 15–33. https://dx.doi.org/10.1007/164_2016_74.

23. Tamariz L., Harzand A., Palacio A. et al. Uric acid as a predictor of all-cause mortality in heart failure: A meta-analysis. Congest Heart Fail. 2011; 17(1): 25–30. https://dx.doi.org/10.1111/j.1751-7133.2011.00200.x.

24. Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: A paradigm shift in understanding their mechanism of action. Diabetes Care. 2020; 43(3): 508–11. https://dx.doi.org/10.2337/dci19-0074.

25. McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008. https://dx.doi.org/10.1056/NEJMoa1911303.

26. Kosiborod M.N., Jhund P.S., Docherty K.F. et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: Results from the DAPА-HF trial. Circulation. 2020; 141(2): 90–99. https://dx.doi.org/10.1161/CIRCULATIONAHA.119.044138.

27. Verma S., Mazer C.D., Yan A.T. et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019; 140(21): 1693–702. https://dx.doi.org/10.1161/CIRCULATIONAHA.119.042375.

28. Chilton R., Tikkanen I., Cannon C.P. et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 17(12): 1180–93. https://dx.doi.org/10.1111/dom.12572.

29. Mosenzon O., Wiviott S.D., Cahn A. et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial

30. Wheeler D.C., Stefansson B.V., Jongs N. et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: A prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021; 9(1): 22–31. https://dx.doi.org/10.1016/S2213-8587(20)30369-7.

31. Karalliedde J. Кардио- и нефропротективные эффекты глифлозинов помимо снижения уровня гликемии. Российский кардиологический журнал. 2021; 26(3): 84–90.

32. Чикина М.Н., Елисеев М.С., Желябина О.В. Практическое применение национальных клинических рекомендаций по лечению подагры (предварительные данные). Современная ревматология. 2020; 14(2): 97–103.

33. McGill J.B. The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: A bench to bedside review. Diabetes Ther. 2014; 5(1): 43–63. https://dx.doi.org/10.1007/s13300-014-0063-1.

34. Doblado M., Moley K.H. Facilitative glucose transporter 9, a unique hexose and urate transporter. Am J Physiol Endocrinol Metab. 2009; 297(4): E831–E835. https://dx.doi.org/10.1152/ajpendo.00296.2009.

35. Caulfield M.J., Munroe P.B., O’Neill D. et al. SLC2A9 Is a high-capacity urate transporter in humans. PLoS Medicine. 2008; 5(10): e197. https://dx.doi.org/10.1371/journal.pmed.0050197.

36. List J.F., Woo V., Morales E. et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2008; 32(4): 650–57. https://dx.doi.org/10.2337/dc08-1863.

37. Roden M., Merker L., Christiansen A.V. et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: A double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol. 2015; 14: 154. https://dx.doi.org/10.1186/s12933-015-0314-0.

38. Davies M.J., Trujillo A., Vijapurkar U. et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015; 17(4): 426–29. https://dx.doi.org/10.1111/dom.12439.

39. Zhao Y., Xu L., Tian D. et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017; 20(2): 458–62. https://dx.doi.org/10.1111/dom.13101.

40. Xin Y., Guo Y., Li Y. et al. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis. Saudi J Biol Sci. 2019; 26(2): 421–26. https://dx.doi.org/10.1016/j.sjbs.2018.11.013.